Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average ... for a 72-week regimen of semaglutide 7.2 milligram (mg).

semaglutide (25 milligrams) for people with obesity to the U.S. regulatory authorities in the first quarter. So, Novo Nordisk has several investigational GLP-1 products across diabetes and obesity ...

Novo Nordisk (NVO) said its popular diabetes ... The Danish drugmaker said the approval makes semaglutide the first GLP-1 RA drug approved for the indication. Semaglutide is also approved for ...

Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have ... small study that suggests that "low doses" of semaglutide (the active ingredient in Ozempic ...

Novo Nordisk (NYSE ... with a strong focus on GLP-1 receptor agonists. The company's key products, including Ozempic (semaglutide) for diabetes and Wegovy (semaglutide) for obesity, have driven ...